Interleukin-2 activated T cells (T-LAK) express CD16 antigen and are triggered to target cell lysis by bispecific antibody.
Human PBMCs from healthy donors were cultured with 100 U/ml rIL-2 for up to 5 weeks and tested at short and long activation times for the ability to mediate CD3 and CD16 targeted cytotoxicity using chemically cross-linked bispecific antibodies. At each period, LAK activity was augmented with the use of bispecific antibodies (BA), whereas interestingly enough, at later periods (4-5 weeks) when CD16 positive lymphocytes are not present by flow cytometry, CD16 targeted cytotoxicity was induced. We suspected the possibility of CD16 expression on activated T cells and have purified the T cell subpopulations to see the targeted cytotoxicity. Populations enriched for T cells by Percoll density centrifugation, treatment with anti-CD16 plus complement or sorting for CD5+ cells, were all able to mediate CD16 targeted cytotoxicity following activation with rIL-2. These data suggest that IL-2 activated T cells express CD16 in addition to CD3.
Nitta
T
T
Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
Nakata
M
M
Yagita
H
H
Okumura
K
K
D000918:Antibody Specificity; D000943:Antigens, Differentiation; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D003602:Cytotoxicity, Immunologic; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008213:Lymphocyte Activation; D011948:Receptors, Antigen, T-Cell; D011961:Receptors, Fc; D017452:Receptors, IgG; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000943:Antigens, Differentiation; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D007376:Interleukin-2; D011948:Receptors, Antigen, T-Cell; D011961:Receptors, Fc; D017452:Receptors, IgG